NeoGraph Analytics
BiotechnologyNortheast2023 – 2032

US CART Cell Therapies Market Size, Share and Trends Analysis

The US CAR T Cell Therapies Market was valued at $3.5 billion in 2023 and is projected to grow at a CAGR of 22.0% to reach $20.7 billion by 2032. This report analyzes key trends, market drivers, and leading players in this rapidly expanding oncology segment.

Revenue, 2023

$3.5B

Forecast, 2032

$20.7B

CAGR, 2024-2032

22%

Report Coverage

Northeast

Code: us-cart-cell-therapies-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Market Overview

The US CAR T cell therapies market is experiencing robust expansion with a CAGR of 22.0%, driven by breakthrough treatments for hematologic cancers and expanding clinical applications. The market is projected to grow from $3.5 billion in 2023 to $20.7 billion by 2032, reflecting significant clinical adoption and technological advancements.

Market Stage

High growth

Adoption Level

Growing

Key Trends

Expansion beyond hematologic malignancies into solid tumor indicationsRise of allogeneic CAR-T platforms reducing manufacturing complexityIncreasing adoption in community oncology settingsIntegration of AI-driven manufacturing process optimization
02

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 22%

Base Year (2023)

$4.3B

Forecast (2032)

$20.7B

CAGR (2024-2032)

22%

Regional Market Analysis
Market share and growth rate by region

Northeast

#1
Share: 28.5%CAGR: 22.8%

Largest market: USA

South

#2
Share: 32.0%CAGR: 23.5%

Largest market: USA

03

Market Dynamics

  • Rising incidence of blood cancers in the US population
  • FDA approvals for additional indications and product enhancements
  • Increasing healthcare expenditure on innovative oncology therapies
  • Strategic partnerships between biotech firms and major medical centers
04

Market Segmentation

By Type

  • Autologous
  • Allogeneic

By End User

  • Hospitals
  • Specialized Oncology Centers
  • Ambulatory Surgical Centers
05

Regional Analysis

1

Northeast

Lead: USA
CAGR: 22.8%Share: 28.5%

Dominates with concentrated academic medical centers in New York and Massachusetts, driving high adoption rates.

2

South

Lead: USA
CAGR: 23.5%Share: 32.0%

Rapid expansion due to increased hospital capacity in Texas and Florida, with strong community oncology adoption.

3

Midwest

Lead: USA
CAGR: 21.7%Share: 22.5%

Steady growth supported by major cancer centers in Illinois and Ohio, with moderate adoption in rural areas.

4

West

Lead: USA
CAGR: 20.9%Share: 17.0%

Innovation hub in California with high research activity, though slower adoption due to geographic dispersion.

Country-Level Analysis

CountryShareGrowth
USA
100.0%
+22.0%
06

Competitive Landscape

N

Novartis

Switzerland

Leader45.0B

Pioneering autologous CAR-T therapy with Kymriah, focusing on pediatric ALL and DLBCL expansion

Kymriah
G

Gilead Sciences

USA

Leader38.5B

Market leader with Yescarta and Tecartus, expanding into solid tumors through strategic acquisitions

YescartaTecartus
B

Bristol Myers Squibb

USA

Leader42.2B

Leading with Breyanzi and Abecma, strong focus on multiple myeloma and lymphoma applications

BreyanziAbecma
L

Legend Biotech

China

Challenger

Key player in allogeneic CAR-T development with Carvykti, leveraging Chinese manufacturing capabilities

P

Poseida Therapeutics

USA

Challenger

Developing next-gen allogeneic CAR-T platforms using piggyBac technology for improved safety

A

Allogene Therapeutics

USA

Challenger

Focusing exclusively on allogeneic CAR-T therapies with advanced genome editing approaches

07

Recent Developments

25
2025Novartis

FDA approval for Kymriah expansion to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in second-line setting

24
2024Gilead Sciences

Announcement of Yescarta approval for second-line treatment of follicular lymphoma based on ZUMA-5 trial data

24
2024Allogene Therapeutics

Initiation of Phase 3 trial for ALLO-501A targeting multiple myeloma with reduced manufacturing time

24
2024Bristol Myers Squibb

Partnership with Mayo Clinic to establish regional CAR-T centers improving patient access in rural areas

24
2024Legend Biotech

FDA acceptance of Biologics License Application for Carvykti in multiple myeloma consolidation therapy

08

Regulatory Landscape

FDA's accelerated approval pathway for breakthrough therapiesCMS coverage policies for CAR-T therapies under Medicare Part BOncology Care Model (OCM) reimbursement adjustments for complex therapiesFDA guidance on allogeneic cell therapy manufacturing standards
09

Frequently Asked Questions

The US CAR T Cell Therapies Market was valued at $3.5 billion in 2023 and is projected to reach $20.7 billion by 2032.
The market is expected to grow at a CAGR of 22.0% from 2023 to 2032.
Primary drivers include rising cancer incidence, FDA approvals for new indications, increasing healthcare expenditure on innovative therapies, and strategic partnerships between biotech firms and major medical centers.
Lymphoma represents the largest segment with 45.0% market share, driven by multiple FDA approvals for diffuse large B-cell lymphoma (DLBCL) treatments.